Jeffrey Wiese
Suggested For You
perspectives
May 13th, 2026
Beyond Data Cleaning: A Strategic Shift for Clinical Data Management under ICH E6 (R3)
news
May 12th, 2026
MMS Strengthens Science-Led Global Leadership, Naming Ben Dudley as President
perspectives
May 5th, 2026
A Statistician's Reflection: FDA Guidance on Limiting Crossover in Oncology Studies
webinar
May 28th, 2026
How AI Is Being Applied to Accelerate Submission Readiness and Reduce Time to Filing
perspectives
April 27th, 2026
From Stigma to Signal: The Executive Order, CNPV Vouchers, and What Comes Next for Psychedelics
perspectives
April 20th, 2026
The FDA Drug Shortage List Signals Deeper Concerns for the US Medicine Supply Chain
perspectives
April 15th, 2026
Decision-Making in Early-Phase Oncology Trials: Navigating Uncertainty with Evidence Frameworks
perspectives
April 8th, 2026
Four Pillars of My Success as a Clinical Trial Transparency Specialist
webinar
March 26th, 2026
Making the Right Decisions With Incomplete Evidence in Early-Phase Oncology Trials
perspectives
March 25th, 2026
REMS and Labeling Are Strategic Design Decisions, Not Late-Stage Add-Ons
perspectives
March 12th, 2026
AI in Pharma: Autopilot Is Not the Same as Removing the Pilot
webinar
April 30th, 2026
Inside FDA REMS Decision-Making: A Fireside Chat for Sponsors